NuVasive Gains FDA Clearance for COHERE in XLIF

NuVasive received FDA 510(k) clearance for use of the COHERE® Porous PEEK™ implant in XLIF® eXtreme Lateral Interbody Fusion. U.S. commercial launch will occur in 2Q19.

The clearance supports use of the interbody device with autograft and allograft to treat degenerative disc disease, degenerative spondylolisthesis and degenerative...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us